Patent details
EP1267945 Title: GENETICALLY MODIFIED CELLS EXPRESSING A TGF-BETA INHIBITOR, THE CELLS BEING LUNG CANCER CELLS
Basic Information
- Publication number:
- EP1267945
- PCT Application Number:
- PCT/US/2001/010339
- Type:
- European Patent Granted for LU
- Legal Status:
- Lapsed
- Application number:
- EP019264985
- PCT Publication Number:
- WO/2001/074404
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- GENETICALLY MODIFIED CELLS EXPRESSING A TGF-BETA INHIBITOR, THE CELLS BEING LUNG CANCER CELLS
- French Title of Invention:
- CELLULES GENETIQUEMENT MODIFIEES EXPRIMANT UN INHIBITEUR DE TGF-BETA, CES CELLULES ETANT DES CELLULES CANCEREUSES DU POUMON
- German Title of Invention:
- GENETISCH MODIFIZIERTE ZELLEN, WELCHE EINEN TGF-BETA INHIBITOR EXPRIMIEREN, WOBEI DIE ZELLEN LUNGENKREBSZELLEN SIND
- SPC Number:
Dates
- Filing date:
- 30/03/2001
- Grant date:
- 05/10/2011
- EP Publication Date:
- 05/10/2011
- PCT Publication Date:
- 11/10/2001
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 02/01/2003
- EP B1 Publication Date:
- 05/10/2011
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- 30/03/2012
- Expiration date:
- 30/03/2021
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 06/10/2011
- Name:
- NovaRx
- Address:
- 6828 Nancy Ridge Drive, Suite 100, San Diego, CA 92121, United States (US)
Inventor
- Name:
- FAKHRAI Habib
- Address:
- United States (US)
Priority
- Priority Number:
- 193497 P
- Priority Date:
- 31/03/2000
- Priority Country:
- United States (US)
Classification
- Main IPC Class:
- A61K 48/00;
| Filing date | Document type | Number of pages |
|---|